CN114096564A - 抗cd47/抗ctla-4双特异抗体及其制备方法和应用 - Google Patents

抗cd47/抗ctla-4双特异抗体及其制备方法和应用 Download PDF

Info

Publication number
CN114096564A
CN114096564A CN202080050574.3A CN202080050574A CN114096564A CN 114096564 A CN114096564 A CN 114096564A CN 202080050574 A CN202080050574 A CN 202080050574A CN 114096564 A CN114096564 A CN 114096564A
Authority
CN
China
Prior art keywords
antigen
seq
ctla
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080050574.3A
Other languages
English (en)
Inventor
殷刘松
李中道
周铁林
方卓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN114096564A publication Critical patent/CN114096564A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及抗CD47/抗CTLA‑4双特异抗体及其制备方法和应用，所述双特异抗体包括(a)第一抗原结合部分，包括重链可变区(VH)和轻链可变区(VL)，其中VH和VL形成特异性结合CD47的抗原结合位点；以及(b)第二抗原结合部分，包含特异性结合CTLA‑4的单域抗体(sdAb)；其中第一抗原结合部分和第二抗原结合部分相互融合。本发明涉及的双特异抗体能同时阻断两种肿瘤免疫逃逸的方式，因此在肿瘤免疫治疗方面具有更好的效果。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202080050574.3A 2019-07-16 2020-07-16 抗cd47/抗ctla-4双特异抗体及其制备方法和应用 Pending CN114096564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910640002 2019-07-16
CN201910640002X 2019-07-16
PCT/CN2020/102324 WO2021008577A1 (zh) 2019-07-16 2020-07-16 抗cd47/抗ctla-4双特异抗体及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN114096564A true CN114096564A (zh) 2022-02-25

Family

ID=74210055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080050574.3A Pending CN114096564A (zh) 2019-07-16 2020-07-16 抗cd47/抗ctla-4双特异抗体及其制备方法和应用

Country Status (4)

Country Link
US (1) US20220332848A1 (zh)
EP (1) EP4001309A4 (zh)
CN (1) CN114096564A (zh)
WO (1) WO2021008577A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268168A1 (zh) * 2021-06-23 2022-12-29 迈威(上海)生物科技股份有限公司 靶向lag-3和pd-l1的新型双特异抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843923A (zh) * 2016-10-11 2019-06-04 南京传奇生物科技有限公司 针对ctla-4的单结构域抗体及其变体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3661965A4 (en) * 2017-08-02 2022-07-13 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
US20210070855A1 (en) * 2018-01-24 2021-03-11 Nanjing Legend Biotech Co., Ltd. Anti-cd47 antibodies that do not cause significant red blood cell agllutination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843923A (zh) * 2016-10-11 2019-06-04 南京传奇生物科技有限公司 针对ctla-4的单结构域抗体及其变体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTHONY L. SCHWARTZ 等: "CTLA4 and CD47 combinational therapy to extend survival in melanoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15, XP009525477, DOI: 10.1200/JCO.2017.35.15_suppl.e21025 *

Also Published As

Publication number Publication date
EP4001309A1 (en) 2022-05-25
WO2021008577A1 (zh) 2021-01-21
US20220332848A1 (en) 2022-10-20
EP4001309A4 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
US11919970B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
RU2725811C1 (ru) Антитела против 4-1bb человека и их применение
CN114072426B (zh) 抗cd47/抗pd-1双特异抗体及其制备方法和应用
US10118964B2 (en) Construction and application of bispecific antibody HER2xCD3
KR20210113265A (ko) 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도
US20200024358A1 (en) Trispecific antigen binding proteins
JP7462611B2 (ja) Ｏｘ４０結合性ポリペプチド及びその使用
US20220267475A1 (en) Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
US11753481B2 (en) Bispecific antibodies against CEACAM5 and CD47
US20210069246A1 (en) Combination therapy using adoptive cell therapy and checkpoint inhibitor
TW202216745A (zh) 包含經修飾ｉｌ－２多肽之多肽及其用途
WO2023202280A1 (zh) 抗B7H6的scFv抗体、其编码基因及其应用
US20220332848A1 (en) Anti-cd47/anti-ctla-4 bispecific antibody and preparation method therefor and application thereof
CN114206940B (zh) 抗cd47/抗lag-3双特异抗体及其制备方法和应用
WO2023093811A1 (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
WO2023004304A1 (en) Cd8-binding polypeptides and uses thereof
US20240091262A1 (en) Mage-a4 peptide dual t cell engagers
TW202334193A (zh) 靶向γδ T細胞之經修飾IL-2多肽及其用途
TW202334233A (zh) 結合γδ T細胞之多肽及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination